Immunotherapy for Skin Cancer Precursors to Prevent Skin Cancer

针对皮肤癌前体的免疫疗法可预防皮肤癌

基本信息

批准号：
10844016
负责人：
Shadmehr Demehri
金额：
$ 1.63万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-05 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10844016
关键词：
Actinic keratosis Address Affect Aftercare Animal Model Antigen Presentation Biological Assay CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes Calcipotriene Cells Cellular Immunity Cellular Stress Characteristics Chemopreventive Agent Clinical Clinical Trials Cytoprotection Data Development Disease remission Disseminated Malignant Neoplasm Double-Blind Method Effector Cell Epidermis Exposure to Face Fluorouracil Goals Immune Immune response Immune system Immunity Immunologic Memory Immunoprevention Immunotherapy Individual Infection Infiltration Ligands Longitudinal Studies Malignant Neoplasms Mediating Memory Morbidity - disease rate Mus Nature Outcome Outcome Study Participant Pathway interactions Patients Phase Premalignant Cell Public Health Randomized Recurrence Research Risk Risk Reduction Role Sampling Scalp structure Signal Induction Signal Transduction Site Skin Skin Cancer Skin Carcinogenesis Skin Carcinoma Squamous cell carcinoma T memory cell T-Cell Activation T-Lymphocyte TSLP gene Testing Therapeutic Uses Tissues Treatment Cost Tumor Immunity Ulcer United States Vaseline Work antitumor effect cancer diagnosis cancer immunotherapy cancer invasiveness carcinogenesis cell type clinical trial participant combat high risk immune activation innovation laser capture microdissection melanoma mortality neoplastic cell organ transplant recipient pre-clinical prevent protective effect recruit response skin cancer prevention skin squamous cell carcinoma success synergism tissue resident memory T cell transcriptome sequencing tumor

项目摘要

Project Summary/Abstract: Recent success in utilizing patients’ own immune cells to combat metastatic cancers highlights the ability of the immune system in providing sustained remission for patients with late-stage cancers like melanoma. However, the role of the immune system in eliminating premalignant cells and preventing their progression to invasive cancers remains uncertain. To determine the benefit of activating the immune system to prevent cancer development and recurrence, we study the immune pathways that lead to effective immune activation against early phases of skin cancer development. Non-melanoma Skin cancers (NMSCs) are collectively the most commonly diagnosed cancers in the United States. cutaneous squamous cell carcinoma (SCC) is associated with severe morbidities including disfigurement, ulceration and infection, and a mortality rate similar to that of melanoma. Importantly, the SCC precursors can be clinically identified and treated. Based on compelling preclinical data, we have performed a randomized double-blind clinical trial in which we find topical calcipotriol together with 5-fluorouracil (5-FU) to promote a robust adaptive immune activation against skin cancer precursors, actinic keratoses, and their complete clearance. Importantly, this immunotherapy led to a significantly lower risk of SCC compared to 5-FU monotherapy group in 3 years post-trial. In order to determine the precise mechanism of calcipotriol plus 5-FU action against early premalignant cells in the skin, and to fully harness its potential to prevent skin cancer, we aim to (1) determine the signals that direct the immune cells to the premalignant cells treated with calcipotriol plus 5-FU combination, (2) investigate the mechanism by which these activated immune cells eliminate the targeted tumor cells, and (3) identify the immune cells and factors that mediate the long-term protective effects of calcipotriol plus 5-FU against SCC. The outcomes of the proposed research will establish a fundamental role for immune activation in combating the early stages of skin cancer development and provide the rationale for the use of calcipotriol plus 5-FU combination in skin cancer immunotherapy and immunoprevention.

项目摘要/摘要：最近成功使用患者自己的免疫细胞来对抗转移性癌症的成功突出了免疫系统可为黑色素瘤等晚期癌症患者提供持续缓解。然而，免疫系统在消除预施加细胞并防止其侵入性的作用中的作用癌症仍然不确定。确定激活免疫系统预防癌症的好处开发和复发，我们研究导致有效免疫激活的免疫病道皮肤癌发展的早期阶段。非黑色素瘤皮肤癌（NMSC）统称最大在美国通常被诊断出癌症。皮肤鳞状细胞癌（SCC）是相关的严重的病毒性包括毁容，溃疡和感染，以及与之相似的死亡率黑色素瘤。重要的是，可以在临床上鉴定和处理SCC前体。基于引人注目临床前数据，我们进行了一项随机的双盲临床试验，其中我们发现了钙钙钙三醇与5-氟尿嘧啶（5-FU）一起促进针对皮肤癌的强大适应性免疫激活前体，活化的角膜生成及其完整的清除率。重要的是，这种免疫疗法导致了在审前3年内，与5-FU单药治疗组相比，SCC的风险明显降低。为了确定钙三醇加5-FU作用对皮肤中早期细胞的精确机制，并完全利用其预防皮肤癌的潜力，我们的目标是（1）确定将免疫细胞引导到的信号用钙三醇加5-FU组合处理的预示例细胞，（2）研究的机制这些激活的免疫细胞消除了靶向的肿瘤细胞，（3）鉴定了免疫细胞和因子介导钙三醇加5-FU对SCC的长期保护作用。结果拟议的研究将确定免疫激活在对抗皮肤早期阶段的基本作用癌症发展并提供了在皮肤癌中使用钙蛋白酶加5-FU组合的基本原理免疫疗法和免疫预防。